Accelerated approval in the United States and conditional marketing authorisation in the European Union allow certain medicines to reach patients before all the evidence normally expected at approval is available. Both routes leave questions to be answered after authorisation. Their legal tests, however, differ: FDA accelerated approval centers on an endpoint reasonably likely to predict clinical benefit; EU conditional authorisation permits a less comprehensive clinical evidence package when defined requirements are met.
For biotech investors, the practical issue is what remains unfinished. An approval announcement should prompt a review of the supporting evidence, required studies and funding needed to complete them. Treating the event as the end of development can distort both revenue forecasts and spending assumptions. This guide examines those remaining obligations; the broader FDA and EMA approval processes provide the context for application reviews and regulatory decisions.
FDA Accelerated Approval and EU Conditional Authorisation Compared
The two routes address a similar problem: patients with serious disease may benefit from access before a conventional development programme has answered every important question. They do not provide interchangeable regulatory status. In a company analysis, record the route separately for each jurisdiction and indication rather than applying one approval description to the entire medicine.
| Feature | FDA accelerated approval | EU conditional marketing authorisation |
|---|---|---|
| Central evidence issue | An effect on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit | Clinical data are less comprehensive than normally required, but the benefit-risk balance is positive |
| Evidence still expected | Verification and description of anticipated clinical benefit, usually through confirmatory studies | Comprehensive data supplied through agreed specific obligations |
| Time structure | Study conditions and deadlines apply; it is not an annually renewable authorisation | Authorisation is valid for one year and renewable annually |
| Successful completion | The indication can receive traditional approval | The authorisation can become standard, without the conditional specific obligations |
| Unfavorable outcome | Possible withdrawal of the affected approval | Possible non-renewal, suspension or revocation |
What Evidence Supports FDA Accelerated Approval?
FDA accelerated approval applies to medicines for serious conditions addressing an unmet medical need. Its defining feature is the evidence used to support earlier approval: a surrogate endpoint, or an intermediate clinical endpoint, reasonably likely to predict clinical benefit. A surrogate measures something other than the benefit itself, such as a laboratory marker or an imaging finding. An intermediate clinical endpoint measures a therapeutic effect earlier than the longer-term outcome of interest. FDA evaluates the scientific support for that prediction, and the studies establishing the treatment effect must be adequate and well controlled. These requirements appear in the FDA description of accelerated approval evidence standards.
The distinction is between demonstrating an effect and establishing what that effect means for patients. A medicine might shrink tumors without yet establishing whether patients live longer or function better. That leaves an evidence gap, even if the measured response is persuasive enough to support earlier access. When reviewing an application or approval announcement, identify the measured endpoint first, then the benefit it is expected to predict. The guide to clinical endpoints and treatment benefit covers that distinction in more detail.
The Endpoint Requires a Contextual Assessment
Do not assign an investment value to a biomarker result in isolation. Ask how convincingly the treatment changed it, how long the effect lasted and whether the study population matches the proposed commercial population. Then examine the unresolved question. Is the uncertainty mainly about durability, a later clinical outcome, or the balance between benefit and toxicity? These are different risks. An unusually large early effect may justify closer attention, but it does not supply missing follow-up. Likewise, a precise measurement can still leave uncertainty about whether the measured change matters enough to patients.
A useful research note separates observed findings from expectations. “The treatment changed the marker” belongs in the first category; “the change will produce a durable clinical benefit,” in the second until supporting evidence resolves it. Keep that separation in the valuation model too. Otherwise, a prediction accepted for regulatory purposes can become an assumed commercial certainty without an explicit investment decision.
What Evidence Supports EU Conditional Marketing Authorisation?
EU conditional marketing authorisation is available before comprehensive clinical safety and efficacy data have been supplied, provided all four legal requirements are satisfied. The medicine must have a positive benefit-risk balance, the applicant must be likely to provide comprehensive clinical data, an unmet medical need must be fulfilled, and the public health benefit of immediate availability must outweigh the risk created by the missing evidence. These are cumulative requirements under Article 4 of Regulation (EC) No 507/2006. A conditional application therefore needs a credible route to completing the evidence package, alongside evidence supporting access now.
The missing evidence can take several forms. It may concern longer follow-up, a larger clinical database, later outcomes or additional patient groups. EU conditional authorisation is therefore broader than a rule about surrogate endpoints alone. Comprehensive pharmaceutical and nonclinical data should normally be available; public health emergencies provide a qualified exception. The EMA scientific guideline on conditional marketing authorisation sets out these evidence considerations. For an investor, the task is to identify exactly which uncertainty has been accepted and how the proposed additional data will resolve it.
This makes the assessment report more useful than a short description such as “approved on early data.” A shortfall in follow-up creates a different development plan from a shortfall in comparative evidence. Read the rationale alongside the obligations, then ask whether the required work answers the stated concern. Avoid treating every conditional authorisation as carrying the same remaining clinical risk.
Conditional Authorisation Is Different From Faster Review
EU accelerated assessment reduces the assessment timetable; conditional marketing authorisation changes when authorisation may be granted relative to completion of the evidence package. They can be used together, but one does not imply the other. PRIME, a development support scheme, is different again. The EMA comparison of early access mechanisms distinguishes these functions. When a company describes a programme as expedited, identify the actual mechanism before changing assumptions about approval timing or the studies still needed.
Authorisation under exceptional circumstances also differs from conditional authorisation. Under the conditional route, comprehensive data are expected to become available within an agreed timeframe. Under exceptional circumstances, comprehensive data cannot be obtained even after authorisation, and the route normally does not lead to a standard authorisation. This distinction is set out in the EMA criteria for conditional authorisation and exceptional circumstances. The analytical consequence is straightforward: a plan to resolve missing evidence should not be confused with a framework for managing uncertainty that cannot be fully resolved.
What Obligations Remain After Approval?
FDA Confirmatory Trials May Need to Start Before Approval
FDA can require a confirmatory study to be underway before accelerated approval, or within a stated period afterward. The January 2025 draft guidance discusses how FDA would assess whether a trial is underway, including recruitment progress, active sites and the prospects for timely completion. It remains draft guidance, not a binding rule requiring every programme to reach the same enrollment threshold. The distinction between the statutory authority and FDA’s proposed implementation matters when reading the draft guidance on confirmatory trials being underway.
For research purposes, “the trial has started” is too vague. Separate protocol agreement, site activation and actual patient enrollment. A registered study with no recruiting sites offers less evidence of progress than a study enrolling patients across an established network. Ask what has happened, rather than accepting a broad status label. Record the enrollment target, disclosed progress and expected completion date. Where those details are absent, retain the gap in the research note instead of filling it with management’s projected readout date.
The budget must extend through the remaining work. Review cash burn and cash runway against trial completion and regulatory submission, rather than stopping at the approval date. A commercial launch can coexist with a substantial development bill. Revenue assumptions should not substitute for a funding plan.
EU Authorisations Require Annual Renewal
A conditional EU authorisation is valid for one year and renewable annually. The renewal application must include an interim report on fulfillment of the specific obligations and an assessment of the current benefit-risk balance using the accumulated evidence. The annual renewal procedure reviews continuing authorisation; it does not mean that every outstanding study must finish within the first year. The EMA requirements for annual renewal of conditional authorisations describe the documentation and review process.
Keep the renewal date separate from each study deadline. They answer different questions. Renewal concerns whether the conditional authorisation should continue; a study deadline concerns delivery of an agreed piece of evidence. In an investment calendar, track both. Also retain earlier versions of disclosed timelines so a revised forecast does not erase the record of delay. A later date may have a reasonable explanation, but the explanation should be examined alongside the remaining uncertainty and additional spending.
Can the Confirmatory Trial Answer the Remaining Question?
A confirmatory programme needs more than a plausible completion date. Examine whether its population, comparator and endpoint can establish the benefit still in question. FDA’s oncology experience also shows why the confirmatory trial may differ from the original approved setting: commercial availability can make enrollment in a randomized study harder, and confirmatory studies are sometimes conducted in earlier treatment lines. The FDA Project Confirm questions on postapproval studies address these design and recruitment issues. A different population is not automatically a defect, but the reason for the design and its regulatory purpose should be clear.
Review the protocol with the same discipline used before approval. Does the comparator reflect a meaningful alternative? Can subsequent treatments make the outcome harder to interpret? What happens if patients leave the study early? The article on clinical trial design and control groups covers these questions. For this analysis, focus on whether the study can close the approval’s evidence gap. A large trial answering a different question may add useful knowledge without resolving the outstanding obligation.
Separate operational risk from evidentiary risk. Operational risk asks whether enough patients can be enrolled and followed. Evidentiary risk asks whether the resulting data will establish the required benefit. A programme can be strong on one dimension and weak on the other. Rapid enrollment does not rescue an unsuitable endpoint; an excellent protocol does not produce results without patients.
Conversion to Traditional or Standard Approval
Leqembi, or lecanemab, provides a concrete example of the US sequence. FDA granted accelerated approval in January 2023 based on a reduction in amyloid plaques, a surrogate endpoint considered reasonably likely to predict clinical benefit. On July 6, 2023, FDA converted the medicine to traditional approval after reviewing the CLARITY AD confirmatory trial. That randomized study assessed clinical outcomes and supported a finding of slower decline. The FDA announcement of Leqembi’s conversion to traditional approval documents the change in evidence supporting the approval.
The analytical lesson is to identify what changed between the two decisions. Conversion reflects a regulatory assessment of additional evidence, not the passage of time or the accumulation of sales. When reviewing a company’s expected conversion milestone, specify the dataset being submitted and the question it is intended to answer. Then compare the expected decision with the actual regulatory action, including its indication and wording.
Safety Still Belongs in the Assessment
Keep the efficacy result and the safety findings in the same review. An apparently favorable headline can encourage a narrow focus on whether a primary endpoint was met. Instead, examine adverse events, discontinuations and the amount of patient follow-up alongside the measured benefit. The guide to reading clinical safety data provides a framework for that work. In the investment note, state what the new dataset resolves and what it leaves open. Avoid describing conversion as the removal of every future clinical or commercial risk.
What Happens if Evidence Is Late or Unfavorable?
US law permits expedited withdrawal of accelerated approval on several grounds. These include failure to conduct a required study with due diligence, failure of a required study to verify anticipated benefit, other evidence showing the product is not shown to be safe or effective under its conditions of use, and false or misleading promotional materials. The procedure includes notice, an explanation and opportunities for the sponsor to respond; a failed trial does not itself constitute an instantaneous withdrawal decision. The governing provisions are in 21 USC 356(c), covering accelerated approval and expedited withdrawal.
For investors, distinguish the data event from the regulatory event. A negative result changes the evidence immediately, while the eventual regulatory action requires its own assessment. Do not assume that continuing sales establish that the evidence concern has disappeared. Equally, do not model a particular withdrawal date without supporting documentation. Record the regulator’s stated next steps and separate them from management’s proposed response. The broader guide to regulatory setbacks and additional study requirements covers related development consequences.
How Remaining Obligations Affect Biotech Valuation
Model the approved business and the unfinished evidence programme together. A useful valuation distinguishes revenue earned under the initial indication from revenue dependent on a later decision. It should also identify the remaining study costs and the date at which those costs produce decision-ready evidence. The framework for risk-adjusted pipeline valuation can help organize these assumptions. Avoid applying a single probability haircut to revenue if that hides different possible outcomes, such as delayed conversion, further studies or loss of an indication.
A Hypothetical Funding and Timing Example
Consider a hypothetical biotech with $240 million in cash after accelerated approval. Its forecast net cash use, including launch activity, planned trial spending and expected product receipts, is $120 million annually. At that unchanged rate, it has roughly two years of runway. Its confirmatory readout is expected in three years. The approval therefore does not remove the financing gap. This is an illustrative calculation, not a company forecast, but it exposes a useful question: what funds the business between initial commercial access and completion of the evidence programme?
Now test a twelve-month delay. At the same assumed cash-use rate, the extra year requires another $120 million before considering financing costs or changes in operations. A better launch could reduce that requirement; higher spending, increase it. Keep these assumptions explicit rather than moving the readout date without moving the associated cash flows. The guide to testing valuation assumptions and launch timing covers this type of scenario analysis. The purpose is to expose dependencies, not to manufacture a precise share-price target.
Keep market access separate from the evidence milestone too. Do not assume that regulatory conversion produces an immediate, predetermined sales increase. Test that assumption through the reimbursement and adoption analysis, using the relevant market and indication. The article on drug pricing, reimbursement and market access addresses that separate part of the commercial forecast.
Build a Documented Record of the Outstanding Evidence
Maintain one evidence record for each medicine, jurisdiction and indication. This prevents a favorable decision in one setting from being carried into assumptions for another. Start with the approval documentation and current product information, then connect the remaining obligations to the relevant trial records and financial disclosures. The guide to biotech research sources and regulatory documents provides a wider research workflow.
- Approval basis: Record the endpoint, population and evidence accepted at the initial decision.
- Unresolved question: State the benefit or evidence gap still requiring confirmation.
- Required work: Match each obligation to its study, deliverable and deadline.
- Execution: Track enrollment, follow-up and changes to the disclosed timetable.
- Funding: Identify the cash required to reach submission and regulatory review.
Update the record when new results appear, retaining the earlier assumptions. Compare the full findings with the required evidence rather than relying on the phrase “positive trial.” The guide to reading clinical trial results supports that assessment. A useful note makes the next decision testable: which data must arrive, when they are expected, and what would cause the investment assumptions to change.